title: Gemfibrozil in late preterm and term neonates with moderate jaundice: a randomized controlled trial.
abstract: OBJECTIVE
  To determine, if oral Gemfibrozil is effective in decreasing the duration of phototherapy by at least 24 hours in neonates >34 weeks gestation with non-hemolytic jaundice, as compared to placebo.
  
  
  METHODS
  Double blind placebo controlled randomized controlled trial.
  
  
  METHODS
  Tertiary care neonatal unit in north India.
  
  
  METHODS
  Ninety seven neonates >34 weeks gestation with non-hemolytic jaundice within first 7 days of life requiring phototherapy.
  
  
  METHODS
  Two doses of Gemfibrozil (60 mg/kg/dose) or placebo, 12 hours apart. Babies were treated with single surface special blue light phototherapy. Serum total bilirubin (STB) was measured 8 hourly. Phototherapy was stopped if two consecutive STB values were below phototherapy zone.
  
  
  METHODS
  Duration of phototherapy.
  
  
  RESULTS
  The median (IQR) duration of phototherapy was 40 (30, 60) hours in Gemfibrozil and 36 (19, 55) hours in the placebo group (P=0.13). The peak STB levels were 16.8 +/- 2.7 mg/dL and 16.3 +/- 2.3 mg/dL in Gemfibrozil and placebo groups, respectively. No side effect of the drug or placebo was noticed.
  
  
  CONCLUSIONS
  Two doses of gemfibrozil (60 mg/kg/dose) given 12 hours apart were not able to reduce the duration of phototherapy, or peak bilirubin level in babies > 34 weeks gestation with non-hemolytic jaundice in the first week of life. Gemfibrozil was not associated with any side effects.
authors.affiliation: Neonatal unit, Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
authors.lastname: Jaikrishan
authors.forename: Praveen
authors.initials: P
authors.lastname: Kumar
authors.forename: Anil
authors.initials: A
authors.lastname: Narang
mesh_terms: D001663:Bilirubin / Q000097:blood; D016009:Chi-Square Distribution; D004311:Double-Blind Method; D015248:Gemfibrozil / Q000009:adverse effects / Q000627:therapeutic use*; D005955:Glucosephosphate Dehydrogenase Deficiency; D006801:Humans; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000188:drug therapy*; D016015:Logistic Models; D010789:Phototherapy; D016896:Treatment Outcome
chemical_list: D015248:Gemfibrozil; D001663:Bilirubin